tbuckley/cabot-search huggingface dataset:
EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria
Authors: Désirée van der Heijde, Annette H M van der Helm-van Mil, Daniel Aletaha, Clifton O Bingham, Gerd R Burmester, Maxime Dougados, Paul Emery, David Felson, Rachel Knevel, Tore K Kvien, Robert B M Landewé, Cédric Lukas, Iain McInnes, Alan J Silman, Josef S Smolen, Ewa Stanislawska-Biernat, Angela Zink, Bernard Combe
Journal: Annals of the Rheumatic Diseases (2013)

The aim of this report was to propose a definition for erosive disease in the context of inflammatory arthritis in light of the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) criteria for use in clinical practice and studies. A EULAR task force was formed including 16 rheumatologists and one rheumatology fellow. The process was both evidence based and consensus based, and included, between March 2010 and April 2012, analyses of data from two cohorts, two face-to-face meetings, one online voting and one teleconference. The Leiden Early Arthritis Cohort and the French ESPOIR cohort were used for the evidence-based part. The outcome measures, which were initiation of methotrexate therapy, or any disease-modifying antirheumatic drug therapy within the first year of disease and arthritis persistency over 5 years, were studied with the aim to give the best definition of erosive disease. A decision was made to select a definition with a high specificity and focus on patients who did not otherwise fulfil the 2010 ACR/EULAR RA criteria (&lt;6 points). By a unanimous vote the following definition was selected: erosive disease for use in the 2010 ACR/EULAR RA classification criteria is defined when an erosion (defined as a cortical break) is seen in at least three separate joints at any of the following sites: the proximal interphalangeal, the metacarpophalangeal, the wrist (counted as one joint) and the metatarsophalangeal joints on radiographs of both hands and feet. A highly specific definition for erosive disease has thus been formulated.
Design requirements and potential target users for brain-computer interfaces – recommendations from rehabilitation professionals
Authors: Femke Nijboer, Danny Plass-Oude Bos, Yvonne Blokland, René van Wijk, Jason Farquhar
Journal: Brain-Computer Interfaces (2014)

It is an implicit assumption in the field of brain-computer interfacing (BCI) that BCIs can be satisfactorily used to access augmentative and alternative communication (AAC) methods by people with severe physical disabilities. A one-day workshop and focus group interview was held to investigate this assumption. Rehabilitation professionals (N = 28) were asked to critically assess current BCI technology, recommend design requirements and identify target users. The individual answers were analyzed using the theoretical framework of grounded theory. None of the participants expressed a perception of added value of current BCIs over existing alternatives. A major criticism (and requirement) was that the usability of BCI systems should significantly improve. Target users are only those who can hardly or not at all use alternative access technologies. However, such persons often have concurrent physical, sensory, and cognitive problems, which could complicate BCI use. If successful BCI use continues to require a user to sit motionlessly and have intact cognition, then – as previously implicitly assumed – people in the locked-in state (resulting from late-stage amyotrophic lateral sclerosis, multiple sclerosis, spinal muscular atrophy type II or classic or total locked-in syndrome) and people with high spinal cord injury (C1/C2) could be target users.
Immune Phenotype Predicts Risk for Posttransplantation Squamous Cell Carcinoma
Authors: Robert P. Carroll, David San Segundo, Kevin Hollowood, Teresa Marafioti, Taane G. Clark, Paul N. Harden, Kathryn J. Wood
Journal: Journal of the American Society of Nephrology (2010)

Cutaneous squamous cell cancer (SCC) affects up to 30% of kidney transplant recipients (KTRs) within 10 years of transplantation. There are no reliable clinical tests that predict those who will develop multiple skin cancers. High numbers of regulatory T cells associate with poor prognosis for patients with cancer in the general population, suggesting their potential as a predictive marker of cutaneous SCC in KTRs. We matched KTRs with (<i>n</i> = 65) and without (<i>n</i> = 51) cutaneous SCC for gender, age, and duration of immunosuppression and assessed several risk factors for incident SCC during a median follow-up of 340 days. Greater than 35 peripheral FOXP3<sup>+</sup>CD4<sup>+</sup>CD127<sup>low</sup> regulatory T cells/μl, &lt;100 natural killer cells/μl, and previous SCC each significantly associated with increased risk for new cutaneous SCC development (hazard ratio [HR] 2.48 [95% confidence interval (CI) 1.04 to 5.98], HR 5.6 [95% CI 1.31 to 24], and HR 1.33 [95% CI 1.15 to 1.53], respectively). In addition, the ratio of CD8/FOXP3 expression was significantly lower in cutaneous SCC excised from KTRs (<i>n</i> = 25) compared with matched SCC from non-KTRs (<i>n</i> = 25) and associated with development of new cutaneous SCCs. In summary, monitoring components of the immune system can predict development of cutaneous SCC among KTRs.
Predictive Value of Aurora-A/STK15 Expression for Late Stage Epithelial Ovarian Cancer Patients Treated by Adjuvant Chemotherapy
Authors: Silke Lassmann, Yi Shen, Uta Jütting, Philipp Wiehle, Axel Walch, Gerald Gitsch, Annette Hasenburg, Martin Werner
Journal: Clinical Cancer Research (2007)

Abstract Purpose: To investigate the expression and regulation of the centrosomal kinase Aurora-A/STK15 (AURKA) in epithelial ovarian cancers and to determine the prognostic and predictive value of this marker for patients with late stage epithelial ovarian cancer treated by distinct adjuvant chemotherapies. Experimental Design: Archival resection specimens of epithelial ovarian cancers (n = 115) and nonneoplastic ovaries (n = 28) were analyzed for AURKA mRNA and protein expression by microdissection and quantitative reverse transcriptase-PCR and immunohistochemistry. AURKA DNA copy numbers were measured by fluorescence in situ hybridization in 37 cases. Statistical evaluation was done with respect to clinicopathologic variables, disease-free survival, and overall survival. Results: AURKA mRNA expression was significantly elevated in cancers (P &amp;lt; 0.001) and correlated with AURKA protein expression (P = 0.0134). Overexpression of AURKA protein was detected in 68 of 107 (63.5%) cases and was linked with increased AURKA DNA copy numbers (P = 0.0141) and centromere 20 aneusomy (P = 0.0137). Moreover, AURKA overexpression was associated with improved overall survival in optimal debulked patients receiving taxol/carboplatin therapy (n = 43, P = 0.018). Finally, in an exploratory approach, patients receiving non–taxane-based therapy, AURKA overexpression was predictive for worse overall survival (n = 30, P = 0.049). Conclusions: AURKA overexpression is seen in the majority of late stage epithelial ovarian cancers, most likely due to increased AURKA DNA copy numbers and/or chromosome 20 aneusomy. Importantly, AURKA overexpression may differentially affect taxane and non–taxane-based adjuvant therapy responses. The study sheds new light on AURKA expression and regulation in epithelial cancers in vivo and specifically shows its value as a clinically relevant marker and as a potential therapeutic target per se.
Medical marijuana for cancer
Authors: Joan L. Kramer
Journal: CA A Cancer Journal for Clinicians (2014)

Abstract Answer questions and earn CME/CNE Marijuana has been used for centuries, and interest in its medicinal properties has been increasing in recent years. Investigations into these medicinal properties has led to the development of cannabinoid pharmaceuticals such as dronabinol, nabilone, and nabiximols. Dronabinol is best studied in the treatment of nausea secondary to cancer chemotherapy and anorexia associated with weight loss in patients with acquired immune deficiency syndrome, and is approved by the US Food and Drug Administration for those indications. Nabilone has been best studied for the treatment of nausea secondary to cancer chemotherapy. There are also limited studies of these drugs for other conditions. Nabiximols is only available in the United States through clinical trials, but is used in Canada and the United Kingdom for the treatment of spasticity secondary to multiple sclerosis and pain. Studies of marijuana have concentrated on nausea, appetite, and pain. This article will review the literature regarding the medical use of marijuana and these cannabinoid pharmaceuticals (with emphasis on indications relevant to oncology), as well as available information regarding adverse effects of marijuana use. CA Cancer J Clin 2015;65: 109–122. © 2014 American Cancer Society.
Understanding cellular function and disease with comparative pathway analysis
Authors: Melissa J Davis, Mark A Ragan
Journal: Genome Medicine (2013)

Pathway analysis is important in interpreting the functional implications of high-throughput experimental results, but robust comparison across platforms and species is problematic. A new approach, Pathprinting, provides a cross-platform, cross-species comparative analysis of pathway expression signatures. This method calculates pathway-level statistics from gene expression across nearly 180,000 microarrays in the Gene Expression Omnibus. Pathprinting can accurately retrieve phenotypically similar samples and identify sets of human and mouse genes that are prognostic in cancer. See related Research paper, http://genomemedicine.com/content/5/7/68.
Effects of Reduced Hematocrit on Erythrocyte Velocity and Fluorescein Transit Time in the Cerebral Microcirculation of the Mouse
Authors: William I. Rosenblum
Journal: Circulation Research (1971)

The red blood cell velocity and the arteriole-to-venule transit time of sodium fluorescein were measured in the pial microcirculation of 15 mice immediately before and after phlebotomy and hemodilution. The acute anemic state produced by the phlebotomy and hemodilution was accompanied by an increase in the velocity of the red blood cells and of the fluorescent plasma. Such increments in velocity must be attributable to either an increased blood pressure or a fall in cerebrovascular resistance. Increases in pressure were generally absent, as was vasodilation, one cause of a decreased resistance. On the other hand, decreased blood viscosity accompanies a fall in hematocrit and could therefore account for a decreased vascular resistance in every animal. These data are consonant with earlier reports in animals and man of an increased cerebral blood flow accompanying anemia. Moreover, the data support those workers who attributed this increase in flow at least partly to a decrease in blood viscosity.
EMG evaluation of hip adduction exercises for soccer players: implications for exercise selection in prevention and treatment of groin injuries
Authors: Andreas Serner, Markus Due Jakobsen, Lars Louis Andersen, Per Hölmich, Emil Sundstrup, Kristian Thorborg
Journal: British Journal of Sports Medicine (2013)

Exercise programmes are used in the prevention and treatment of adductor-related groin injuries in soccer; however, there is a lack of knowledge concerning the intensity of frequently used exercises.Primarily to investigate muscle activity of adductor longus during six traditional and two new hip adduction exercises. Additionally, to analyse muscle activation of gluteals and abdominals.40 healthy male elite soccer players, training >5 h a week, participated in the study. Muscle activity using surface electromyography (sEMG) was measured bilaterally for the adductor longus during eight hip adduction strengthening exercises and peak EMG was normalised (nEMG) using an isometric maximal voluntary contraction (MVC) as reference. Furthermore, muscle activation of the gluteus medius, rectus abdominis and the external abdominal obliques was analysed during the exercises.There were large differences in peak nEMG of the adductor longus between the exercises, with values ranging from 14% to 108% nEMG (p<0.0001). There was a significant difference between legs in three of the eight exercises (35-48%, p<0.0001). The peak nEMG results for the gluteals and the abdominals showed relatively low values (5-48% nEMG, p<0.001).Specific hip adduction exercises can be graded by exercise intensity providing athletes and therapists with the knowledge to select appropriate exercises during different phases of prevention and treatment of groin injuries. The Copenhagen Adduction and the hip adduction with an elastic band are dynamic high-intensity exercises, which can easily be performed at any training facility and could therefore be relevant to include in future prevention and treatment programmes.
Perception, action, and motor control: Interaction does not necessarily imply common structures
Authors: L. Pisella, A. Kritikos, Y. Rossetti
Journal: Behavioral and Brain Sciences (2001)

The Theory of Event Coding (TEC) provides a preliminary account of the interaction between perception and action, which is consistent with several recent findings in the area of motor control. Significant issues require integration and elaboration, however; particularly, distractor interference, automatic motor corrections, internal models of action, and neuroanatomical bases for the link between perception and action.
Slow moderate pressure recruitment maneuver minimizes negative circulatory and lung mechanic side effects: evaluation of recruitment maneuvers using electric impedance tomography
Authors: Helena Odenstedt, Sophie Lindgren, Cecilia Olegård, Karin Erlandsson, Sven Lethvall, Anders Åneman, Ola Stenqvist, Stefan Lundin
Journal: Intensive Care Medicine (2005)
Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer
Authors: G. V. Scagliotti
Journal: JNCI Journal of the National Cancer Institute (2003)

Surgery is the primary treatment for patients with stage I, II, or IIIA non-small-cell lung cancer (NSCLC). However, long-term survival of NSCLC patients after surgery alone is largely unsatisfactory, and the role of adjuvant chemotherapy in patient survival has not yet been established.Between January 1994 and January 1999, 1209 patients with stage I, II, or IIIA NSCLC were randomly assigned to receive mitomycin C (8 mg/m2 on day 1), vindesine (3 mg/m2 on days 1 and 8), and cisplatin (100 mg/m2 on day 1) every 3 weeks for three cycles (MVP group; n = 606) or no treatment (control group; n = 603) after complete resection. Randomization was stratified by investigational center, tumor size, lymph-node involvement, and the intention to perform radiotherapy. The primary endpoint was overall survival and secondary endpoints were progression-free survival and toxicity associated with adjuvant treatment. Survival curves were analyzed using the log-rank test. All statistical tests were two-sided.After a median follow-up time of 64.5 months, there was no statistically significant difference between the two patient groups in overall survival (hazard ratio = 0.96, 95% confidence interval = 0.81 to 1.13; P =.589) or progression-free survival (hazard ratio = 0.89, 95% confidence interval = 0.76 to 1.03; P =.128). Only 69% of patients received the three planned cycles of MVP. Grades 3 and 4 neutropenia occurred in 16% and 12%, respectively, of patients in the MVP arm. Radiotherapy was completed by 65% of patients in the MVP arm and by 82% of patients in the control group. In the multivariable analysis, only disease stage and sex were associated with survival.This randomized trial failed to prospectively confirm a statistically significant role for adjuvant chemotherapy in completely resected NSCLC. Given the poor compliance with the MVP regimen used in this study, future studies should explore more effective treatments.
Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial.
Authors: K D Bardhan, J Naesdal, G Bianchi Porro, M Petrillo, M Lazzaroni, R F Hinchliffe, M Thompson, P Morris, M J Daly, N J Carroll
Journal: Gut (1991)

We tested the hypothesis that the gastric H+/K+ adenosine triphosphatase inhibitor, omeprazole, because of its different mode of action and pronounced inhibitory effect on gastric acid secretion, may be more effective in peptic ulcer that is refractory to histamine H2 receptor antagonist treatment than continuing the same therapy. Altogether 107 patients (duodenal ulcer, n = 88; prepyloric ulcer, n = 14; gastric ulcer, n = 3; mixed sites, n = 2) with refractory peptic ulcer - that is ulcer unhealed after at least two months9 treatment with cimetidine 0.8 g or 1 g daily or with ranitidine 0.3 g daily - were randomly allocated to receive either omeprazole 40 mg daily (n = 54) or to continue treatment with the same H2 receptor antagonist and at the same dose (n = 53) for up to eight weeks. The patients in the two treatment groups were well matched demographically. Healing by 9intent to treat9 analysis was as follows: at four weeks, omeprazole 46 of 54 (85%), H2 receptor antagonist 18 of 53 (34%) (p less than 0.0001); and at eight weeks, 52 of 54 (96%) and 30 of 53 (57%) respectively (p less than 0.0001). One patient was lost to follow up but of the 22 patients whose ulcers were shown to be unhealed at endoscopy after receiving continued H2 receptor antagonist treatment, 21 healed in four to eight weeks when changed to omeprazole. Daytime epigastric pain cleared at four weeks in 43 of 47 (91%) patients on omeprazole and in 32 of 46 (70%) on H2 receptor antagonists (p=0.01) and relief of all dyspeptic symptoms occurred in 39 of 47 (83%) and 23 of 45 (51%) (p=0.0009) patients respectively. Adverse events occurred in 11 of 54 (20%) patients on omeprazole and in 12 of 35 (34%) on cimetidine but in none on ranitidine. The events were mild and none required treatment withdrawal. The commonest event in patients on omeprazole was loose stools or diarrhoea (n=5). Omeprazole was significantly better than continued H2 receptor antagonist treatment for the short term management of refractory peptic ulcer as judged by healing rate and pain relief, and it was safe.
Aberrant Expression of Novel and Previously Described Cell Membrane Markers in Human Breast Cancer Cell Lines and Tumors
Authors: Huayi Huang, Jeff Groth, Khalid Sossey-Alaoui, Lesleyann Hawthorn, Stephanie Beall, Joseph Geradts
Journal: Clinical Cancer Research (2005)

Abstract Purpose: In a previous gene expression array study, we identified some 300 genes that were differentially expressed in human epidermal growth factor receptor tyrosine kinase 2 (HER2)–positive versus HER2-negative breast cancer cells. We have now done validation experiments on a group of three cell membrane components that had previously not been implicated in breast cancer. We also studied the expression of three other cell membrane proteins known to play a role in mammary neoplasia. Experimental Design: By immunohistochemistry, we examined up to 130 archival breast carcinomas for Celsr2, E-cadherin, Kai1, and CD9 expression. The expression levels of NET-6 and TROP-2 were determined by quantitative reverse transcription-PCR in a subset of frozen tumors. We also studied fresh pellets and paraffin-embedded cell buttons of nine human breast cell lines. The relationship between the expression of all six membrane proteins and a variety of pathologic and biological variables, including estrogen receptor, HER2, and epidermal growth factor receptor status, was also examined. The NET-6 gene was transfected into a low-expressing cell line, and the effect on cellular morphology, growth, and invasion in vitro was recorded. Results: Celsr2 was down-regulated in one cell line and in 7% of breast cancers. E-cadherin, Kai1, and CD9 were down-regulated in 35%, 76%, and 79% of tumors, respectively, confirming the important role of these markers in human mammary neoplasia. In breast cancer cell lines and tissues, TROP-2 was generally expressed at low levels, although a few specimens showed relative overexpression. NET-6 levels were lower in HER2-negative breast carcinoma cells. In addition, NET-6 was markedly down-regulated in estrogen receptor–negative breast cancers, and expression was lowest in “basal-like” tumors. Ectopic expression of NET-6 in low-expressing MDA-MB-231 cells altered cellular morphology, inhibited growth in vitro, and decreased invasion in a Boyden chamber assay. Conclusions: We have confirmed the expression of three new membrane markers that had previously not been implicated in human breast cancer, and one of them (NET-6) was correlated with HER2 and estrogen receptor status. NET-6 levels were decreased in estrogen receptor–negative and high-grade tumors, and ectopic expression of this gene had an inhibitory effect on proliferation and invasion. Thus, NET-6 may represent a novel breast cancer suppressor gene.
Azithromycin and the Risk of Cardiovascular Death
Authors: Wayne A. Ray, Katherine T. Murray, Kathi Hall, Patrick G. Arbogast, C. Michael Stein
Journal: New England Journal of Medicine (2012)

Although several macrolide antibiotics are proarrhythmic and associated with an increased risk of sudden cardiac death, azithromycin is thought to have minimal cardiotoxicity. However, published reports of arrhythmias suggest that azithromycin may increase the risk of cardiovascular death.
Multidisciplinary Care and Pursuit of Active Surveillance in Low-Risk Prostate Cancer
Authors: Ayal A. Aizer, Jonathan J. Paly, Anthony L. Zietman, Paul L. Nguyen, Clair J. Beard, Sandhya K. Rao, Irving D. Kaplan, Andrzej Niemierko, Michelle S. Hirsch, Chin-Lee Wu, Aria F. Olumi, M. Dror Michaelson, Anthony V. D'Amico, Jason A. Efstathiou
Journal: Journal of Clinical Oncology (2012)

Multidisciplinary clinics offer a unique approach to the management of patients with cancer. Yet, limited data exist to show that such clinics affect management. The purpose of this study was to determine whether consultation at a multidisciplinary clinic is associated with selection of active surveillance in patients with low-risk prostate cancer.The study comprised 701 men with low-risk prostate cancer managed at three tertiary care centers in Boston, MA in 2009. Patients either obtained consultation at a multidisciplinary prostate cancer clinic, at which they were seen by a combination of urologic, radiation, and medical oncologists in a concurrent setting, or they were seen by individual practitioners in sequential settings. The primary outcome was selection of active surveillance.Crude rates of selection of active surveillance in patients seen at a multidisciplinary clinic were double that of patients seen by individual practitioners (43% v 22%), whereas the proportion of men treated with prostatectomy or radiation decreased by approximately 30% (P < .001). On multivariate logistic regression, older age (odds ratio [OR], 1.09; 95% CI, 1.05 to 1.12; P < .001), unmarried status (OR, 1.66; 95% CI, 1.01 to 2.72; P = .04), increased Charlson comorbidity index (OR, 1.37; 95% CI, 1.06 to 1.77; P = .02), fewer positive cores (OR, 0.92; 95% CI, 0.90 to 0.94; P < .001), and consultation at a multidisciplinary clinic (OR, 2.15; 95% CI, 1.13 to 4.10; P = .02) were significantly associated with pursuit of active surveillance.Multidisciplinary care is associated with increased selection of active surveillance in men with low-risk prostate cancer. This finding may have an important clinical, social, and economic impact.